ReviewNature reviews. Disease primers2026
Bulimia nervosa.
Review in Nature reviews. Disease primers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bulimia nervosa (BN) is common and has a global presence and burden. BN shares features with anorexia nervosa and binge eating disorder, but its cardinal feature is recurrent binge eating followed by extreme weight control or compensatory behaviours in association with high levels of weight and shape, and other body image and eating, preoccupations. The last three decades have seen advances in understanding the risk factors and psychobehavioural mechanisms of BN. These advances have informed primary prevention programmes that are effective in preventing the onset of risk factors and, in one selective programme, the onset of BN itself. First-line treatment for BN is psychological therapy, namely cognitive behaviour therapy for eating disorders. However, the challenge of a large treatment gap and the need to improve prevention and early detection of BN remains. Adaptations of treatments to increase their accessibility and reduce cost, alongside the growth of co-design and incorporation of lived experience expertise in research, are assisting in developing programmes that may effectively close this treatment gap. An increasingly sophisticated approach to understanding the neuroscience of BN has the potential to inform novel treatments in both psychological and biological spheres.
Indexed as
Identifiers
42532999What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.